Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

被引：0

作者：

Chang-Min Choi

Se-Jin Jang

Seong-Yeol Park

Yong-Bock Choi

Jae-Heon Jeong

Dae-Seok Kim

Hyun-Kyoung Kim

Kang-Seo Park

Byung-Ho Nam

Hyeong-Ryul Kim

Soo-Youl Kim

Kyeong-Man Hong

机构：

[1] University of Ulsan,Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine

[2] University of Ulsan,Department of Pathology, Asan Medical Center, College of Medicine

[3] National Cancer Center,Cancer Cell and Molecular Biology Branch, Research Institute

[4] Kyung Hee University,Department of Medical Oncology & Hematology, Kyung Hee Medical Center

[5] National Cancer Center,Cancer Biostatics Branch, Research Institute

[6] University of Ulsan,Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, College of Medicine

来源：

Molecular Cancer | / 10卷

关键词：

H1703 Cell; Pemetrexed; NSCLC Cell; Crizotinib; NSCLC Cell Line;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

下载

共 50 条

[1] Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer
Choi, Chang-Min
Jang, Se-Jin
Park, Seong-Yeol
Choi, Yong-Bock
Jeong, Jae-Heon
Kim, Dae-Seok
Kim, Hyun-Kyoung
Park, Kang-Seo
Nam, Byung-Ho
Kim, Hyeong-Ryul
Kim, Soo-Youl
Hong, Kyeong-Man
MOLECULAR CANCER, 2011, 10
[2] Transglutaminase 2 as an independent prognostic marker for the survival of Korean patients with non-small cell lung cancer
Choi, C-M
Jang, S-J
Nam, B-H
Kim, H-R
Kim, S-Y
Hong, K-M
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S14 - S14
[3] Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients
Zhu Chihong
Ling Yutian
Wan Danying
Jiang Ruibin
Sheng Huaying
Gu Linhui
Feng Jianguo
ONCOTARGET, 2017, 8 (28) : 45577 - 45584
[4] Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
Kang-Seo Park
Hyun-Kyoung Kim
Jung-Hwa Lee
Yong-Bock Choi
Seong-Yeol Park
Sei-Hoon Yang
Soo-Youl Kim
Kyeong-Man Hong
Journal of Cancer Research and Clinical Oncology, 2010, 136 : 493 - 502
[5] Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
Park, Kang-Seo
Kim, Hyun-Kyoung
Lee, Jung-Hwa
Choi, Yong-Bock
Park, Seong-Yeol
Yang, Sei-Hoon
Kim, Soo-Youl
Hong, Kyeong-Man
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 493 - 502
[6] Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients
Song, Zhengbo
Yu, Xinmin
Zhang, Yiping
CANCER BIOLOGY & THERAPY, 2017, 18 (11) : 883 - 887
[7] Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients
Song, Zhengbo
Yu, Xinmin
Zhang, Yiping
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S494 - S494
[8] Clinicopathological features and efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC) - Comparison between adenocarcinoma and non-adenocarcinoma
Kawano, Y
Kashii, T
Katayama, H
Hasegawa, Y
Tokunaga, S
Sumitani, M
Takeda, K
Takifuji, N
Nakajima, R
Tada, H
LUNG CANCER, 2005, 49 : S371 - S371
[9] Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients
Jouinot, Anne
Ulmann, Guillaume
Vazeille, Clara
Durand, Jean-Philippe
Boudou-Rouquette, Pascaline
Arrondeau, Jennifer
Tlemsani, Camille
Fournel, Ludovic
Alifano, Marco
Wislez, Marie
Chapron, Jeanne
Le Bris, Camille
Mansuet-Lupo, Audrey
Damotte, Diane
Neveux, Nathalie
De Bandt, Jean-Pascal
Alexandre, Jerome
Cynober, Luc
Goldwasser, Francois
CLINICAL NUTRITION, 2020, 39 (06) : 1893 - 1899
[10] High level expression of Rad51 is an independent prognostic marker of survival in non-small cell lung cancer patients
Qiao, G
Wu, Y
Yang, X
Zhong, W
Xie, D
Guan, X
Stuerzbecher, H
LUNG CANCER, 2005, 49 : S45 - S45

← 1 2 3 4 5 →